(VIANEWS) - Bruker Corporation (BRKR), ConnectOne Bancorp (CNOB), Littelfuse (LFUS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Bruker Corporation (BRKR)
12.8% sales growth and 26.88% return on equity
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
Bruker Corporation's sales growth this year is expected to be 20.5% and 5.7% for next year.
Year-on-year quarterly revenue growth grew by 19.1%, now sitting on 2.36B for the twelve trailing months.
Volume
Today's last reported volume for Bruker Corporation is 184078 which is 69.04% below its average volume of 594715.
Bruker Corporation's sales growth for the next quarter is 12.8%. The company's growth estimates for the ongoing quarter and the next is a negative 0% and 11.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 26.88%.
Volatility
Bruker Corporation's last day, last week, and last month's current intraday variation average was 4.07%, 2.30%, and 1.36%, respectively.
Bruker Corporation's highest amplitude of average volatility was 4.92% (day), 4.12% (last week), and 3.20% (last month), respectively.
Bruker Corporation's Stock Yearly Top and Bottom Value
Bruker Corporation's stock is valued at $77.97 at 19:22 EST, way below its 52-week high of $92.35 and way higher than its 52-week low of $50.00.
Bruker Corporation's Moving Average
Bruker Corporation's value is below its 50-day moving average of $80.28 and higher than its 200-day moving average of $74.51.2. ConnectOne Bancorp (CNOB)
12.6% sales growth and 12.36% return on equity
ConnectOne Bancorp, Inc. operates as the bank holding company for ConnectOne Bank, a chartered commercial bank that provides various commercial banking products and services.
ConnectOne Bancorp's sales growth this year is anticipated to be 11.4% and 6.6% for next year.
Year-on-year quarterly revenue growth grew by 20.5%, now sitting on 270.46M for the twelve trailing months.
Volume
Today's last reported volume for ConnectOne Bancorp is 67684 which is 45.71% below its average volume of 124690.
ConnectOne Bancorp's sales growth for the next quarter is 12.6%. The company's growth estimates for the ongoing quarter and the next is 16.9% and negative -11%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.36%.
Volatility
ConnectOne Bancorp's last day, last week, and last month's current intraday variation average was 0.72%, 0.94%, and 1.33%, respectively.
ConnectOne Bancorp's highest amplitude of average volatility was 2.43% (day), 2.37% (last week), and 2.83% (last month), respectively.
ConnectOne Bancorp's Stock Yearly Top and Bottom Value
ConnectOne Bancorp's stock is valued at $34.60 at 19:22 EST, under its 52-week high of $35.50 and way above its 52-week low of $17.60.
ConnectOne Bancorp's Moving Average
ConnectOne Bancorp's worth is higher than its 50-day moving average of $32.32 and way above its 200-day moving average of $28.04.3. Littelfuse (LFUS)
12% sales growth and 17.36% return on equity
Littelfuse, Inc. manufactures and sells circuit protection, power control, and sensing products in the Asia-Pacific, the Americas, and Europe.
Littelfuse's sales growth this year is expected to be 40.1% and 6.8% for next year.
Year-on-year quarterly revenue growth grew by 37.8%, now sitting on 1.93B for the twelve trailing months.
Volume
Today's last reported volume for Littelfuse is 76773 which is 17.63% below its average volume of 93206.
Littelfuse's sales growth for the next quarter is 12%. The company's growth estimates for the ongoing quarter and the next is 30.9% and 14.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.36%.
Volatility
Littelfuse's last day, last week, and last month's current intraday variation average was 0.11%, 1.05%, and 1.41%, respectively.
Littelfuse's highest amplitude of average volatility was 2.46% (day), 2.88% (last week), and 3.16% (last month), respectively.
Littelfuse's Stock Yearly Top and Bottom Value
Littelfuse's stock is valued at $314.91 at 19:22 EST, under its 52-week high of $334.84 and way above its 52-week low of $232.15.
Littelfuse's Moving Average
Littelfuse's worth is higher than its 50-day moving average of $294.85 and way above its 200-day moving average of $271.16.4. Luxfer Holdings PLC (LXFR)
11.8% sales growth and 16.32% return on equity
Luxfer Holdings PLC, a materials technology company, designs, manufactures, and supplies high-performance materials, components, and high-pressure gas cylinders for transportation, defense and emergency response, healthcare, and general industrial end-market applications.
Luxfer Holdings PLC's sales growth this year is anticipated to be 13.2% and 6.7% for next year.
Year-on-year quarterly revenue growth grew by 29.2%, now sitting on 344M for the twelve trailing months.
Volume
Today's last reported volume for Luxfer Holdings PLC is 73229 which is 11.23% below its average volume of 82498.
Luxfer Holdings PLC's sales growth for the next quarter is 11.8%. The company's growth estimates for the present quarter and the next is a negative 0% and negative -3.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.32%.
Volatility
Luxfer Holdings PLC's last day, last week, and last month's current intraday variation average was 0.19%, 1.35%, and 2.47%, respectively.
Luxfer Holdings PLC's highest amplitude of average volatility was 1.90% (day), 2.47% (last week), and 3.87% (last month), respectively.
Luxfer Holdings PLC's Stock Yearly Top and Bottom Value
Luxfer Holdings PLC's stock is valued at $21.39 at 19:22 EST, way below its 52-week high of $23.91 and way above its 52-week low of $14.70.
Luxfer Holdings PLC's Moving Average
Luxfer Holdings PLC's worth is higher than its 50-day moving average of $20.80 and higher than its 200-day moving average of $20.95.5. Graco (GGG)
8.8% sales growth and 35.45% return on equity
Graco Inc. designs, manufactures, and markets systems and equipment used to move, measure, control, dispense, and spray fluid and powder materials worldwide.
Graco's sales growth this year is anticipated to be 19.4% and 5.4% for next year.
Year-on-year quarterly revenue growth grew by 38.2%, now sitting on 1.87B for the twelve trailing months.
Volume
Today's last reported volume for Graco is 368531 which is 36.83% below its average volume of 583433.
Graco's sales growth for the next quarter is 8.8%. The company's growth estimates for the current quarter and the next is 8.5% and 8.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 35.45%.
Volatility
Graco's last day, last week, and last month's current intraday variation average was 0.23%, 0.61%, and 0.71%, respectively.
Graco's highest amplitude of average volatility was 0.79% (day), 1.37% (last week), and 1.44% (last month), respectively.
Graco's Stock Yearly Top and Bottom Value
Graco's stock is valued at $77.13 at 19:22 EST, under its 52-week high of $80.48 and way above its 52-week low of $64.34.
Graco's Moving Average
Graco's worth is above its 50-day moving average of $74.38 and above its 200-day moving average of $74.52.6. NeoGenomics (NEO)
7.7% sales growth and 5.42% return on equity
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.
NeoGenomics's sales growth this year is expected to be 12.4% and 16.2% for next year.
Year-on-year quarterly revenue growth declined by 3.3%, now sitting on 484.59M for the twelve trailing months.
Volume
Today's last reported volume for NeoGenomics is 826225 which is 15.42% below its average volume of 976962.
NeoGenomics's sales growth for the next quarter is 7.7%. The company's growth estimates for the ongoing quarter and the next is a negative 233.3% and negative -150%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.42%.
Volatility
NeoGenomics's last day, last week, and last month's current intraday variation average was 0.94%, 3.05%, and 3.24%, respectively.
NeoGenomics's highest amplitude of average volatility was 5.42% (day), 5.96% (last week), and 5.16% (last month), respectively.
NeoGenomics's Stock Yearly Top and Bottom Value
NeoGenomics's stock is valued at $39.00 at 19:22 EST, way under its 52-week high of $61.57 and higher than its 52-week low of $35.71.
NeoGenomics's Moving Average
NeoGenomics's worth is way under its 50-day moving average of $44.06 and way below its 200-day moving average of $45.69.7. Royalty Pharma (RPRX)
6.2% sales growth and 19.76% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is expected to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 2.24B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 2397820 which is 1.21% above its average volume of 2369110.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the ongoing quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.76%.
Volatility
Royalty Pharma's last day, last week, and last month's current intraday variation average was 0.55%, 0.72%, and 1.84%, respectively.
Royalty Pharma's highest amplitude of average volatility was 1.30% (day), 1.95% (last week), and 3.15% (last month), respectively.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $41.98 at 19:22 EST, way under its 52-week high of $53.23 and way above its 52-week low of $34.86.